Neurona Therapeutics

What Neurona Therapeutics does

Neurona Therapeutics is a clinical-stage biotherapeutics company developing allogeneic, off-the-shelf regenerative cell therapies for chronic neurological disorders. Founded in 2015 as a UCSF spinout by scientific founders Cory Nicholas, Arturo Álvarez-Buylla, Arnold Kriegstein, and John Rubenstein, the company industrializes production of human medial ganglionic eminence (MGE)-type GABAergic inhibitory interneurons derived from clinical-grade human pluripotent stem cells. Products are manufactured in Neurona's state-of-the-art cGMP facility in South San Francisco using proprietary stage-wise processes that recapitulate endogenous brain development and yield authentic post-mitotic neuronal and glial cell types with residual stem cells eliminated.

The company's lead product candidate rezanecel (formerly NRTX-1001) is a first-in-class allogeneic inhibitory neuron cell therapy designed as a single-dose, image-guided intracerebral administration intended to provide durable seizure suppression in drug-resistant mesial temporal lobe epilepsy (MTLE). It is being evaluated in two Phase 1/2 trials — NTE001 for unilateral MTLE (NCT05135091, 35+ U.S. sites) and NTE002 for bilateral MTLE (NCT06422923, 11 sites) — with reported low-dose median disabling seizure reductions of 89% (unilateral MTLE with MTS, N=9) and durable efficacy past two years in several subjects, alongside no serious adverse events attributed to product or procedure across 31 dosed participants. A planned pivotal Phase 3 EPIC trial is designed as the primary basis for a future BLA, with first enrollment targeted for 2H 2026. The pipeline also extends to an oligodendrocyte glial cell therapy candidate for demyelinating disorders and a gene-edited neural cell therapy program for CNS-targeted payload delivery, both preclinical.

Neurona is privately-held and pre-revenue with no commercial products approved. The company has raised approximately $283.5M in disclosed equity financing (most recently a $102M oversubscribed round in April 2025 led by Fidelity) plus approximately $30.6M in non-dilutive CIRM grants. On April 17, 2026, UCB S.A. entered into a definitive agreement to acquire Neurona for up to US$1.15 billion (US$650M upfront plus up to US$500M in milestones), with closing expected by end of Q2 2026 subject to anti-trust clearance, positioning rezanecel within UCB's established 30-year epilepsy franchise.

Name

Neurona Therapeutics

Legal name

Neurona Therapeutics, Inc.

Website

https://neuronatherapeutics.com

Company type

Private

Founded year

2015

Operating status

Acquired

Headcount range

101–250 employees

Ownership category

akta.pro rank

Product category

Regenerative Cell Therapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology/CNS Gene Therapies (HLAAACAH)

akta.pro secondary industries

Neural & Spinal Cord Regeneration (HLAAAGAI), Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD)

Keywords

• Regenerative cell therapy
• Neural cell therapies
• Epilepsy biotherapeutics
• Pluripotent stem cell
• Allogeneic cell therapy

Headquarters

HQ city

South San Francisco

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Pre-revenue clinical-stage biotherapeutics: Neurona Therapeutics is a privately-held, clinical-stage biotherapeutics company with no commercial products approved or generating revenue. Its lead candidate rezanecel (NRTX-1001) has not been approved by any regulatory authority; the website explicitly states NONE OF THE NEURONA PRODUCT CANDIDATES HAVE BEEN APPROVED FOR COMMERCIAL DISTRIBUTION. Future anticipated revenue model upon approval is a one-time administration per patient of an allogeneic cell therapy (biologic).
2. Non-dilutive grant funding (CIRM): Multiple non-dilutive grants from the California Institute for Regenerative Medicine (CIRM): $4.8M translational grant (2019), $8.0M (CLIN2-13355, May 2022) for Phase 1/2 unilateral MTLE trial, $3.8M (September 2024) for next-generation neural cell therapy candidate, and $14M (CLIN2-17135, March 2025) for bilateral MTLE Phase 1/2 trial. Grants fund clinical operations but are not revenue.
3. Private equity financing rounds: Capital raised through private equity rounds from VC and strategic investors: $23.5M Series A (Dec 2015), $41.5M (June 2021), $120M (Feb 2024), $102M (April 2025); plus an SEC exempt offering of securities (Dec 2022) for approximately $91.6M with ~$72M sold. These financings support clinical development but are not revenue.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels9 records

Core offering

Neurona Therapeutics is a clinical-stage biotherapeutics company developing allogeneic, off-the-shelf regenerative neural cell therapies derived from human pluripotent stem cells. Its lead product candidate rezanecel (NRTX-1001) is a first-in-class MGE-type GABAergic inhibitory interneuron cell therapy administered as a single image-guided intracerebral dose to durably suppress seizures in drug-resistant mesial temporal lobe epilepsy. The same proprietary hPSC platform is being extended to myelinating glial (oligodendrocyte) cell therapies and gene-edited neural cell therapies for additional chronic neurological disorders, all manufactured in-house at the company's cGMP facility in South San Francisco.

Product overview

Neurona Therapeutics offers a single unified pipeline of wholly-owned, allogeneic, off-the-shelf regenerative neural cell therapies built on a common medial ganglionic eminence (MGE) cell platform derived from clinical-grade human pluripotent stem cells. The portfolio is anchored by the lead product candidate NRTX-1001 (now known as rezanecel), a first-in-class human MGE-type GABAergic inhibitory interneuron cell therapy currently being evaluated in two Phase 1/2 trials (NTE001 for unilateral MTLE and NTE002 for bilateral MTLE) and a planned pivotal Phase 3 EPIC trial in drug-resistant mesial temporal lobe epilepsy. The platform also extends to a myelinating glial (oligodendrocyte) cell therapy candidate for undisclosed demyelinating indications and a gene-edited neural cell therapy program designed for targeted delivery of therapeutic factors to the central nervous system, both currently in preclinical development. All candidates are manufactured in Neurona's state-of-the-art cGMP facility in South San Francisco using a proprietary, stage-wise process that recapitulates endogenous neural development.

Differentiator

Problem solved

Functional benefit

Products and services

• Rezanecel (NRTX-1001) Inhibitory Neuron Cell Therapy Lead allogeneic, off-the-shelf, regenerative cell therapy product candidate composed of human MGE-type GABAergic inhibitory interneurons derived from pluripotent stem cells. Delivered as a single, one-time intracerebral dose targeted to the seizure-onset zone to enhance GABAergic inhibition, reduce seizure activity, and repair affected neural networks. Being investigated in two Phase 1/2 clinical trials (NTE001 for unilateral MTLE, NCT05135091; NTE002 for bilateral MTLE, NCT06422923) and a planned pivotal Phase 3 EPIC trial. Holds FDA RMAT designation (June 2024) and EMA PRIME designation (November 2025).
• Myelinating Glial Cell Therapy (MGE Oligodendrocyte Candidate) Allogeneic oligodendrocyte glial cell therapy candidate derived from the medial ganglionic eminence (MGE) using Neurona's proprietary platform. Designed to insulate (myelinate) neuronal axons and restore myelin in genetic dysmyelination disorders and acquired demyelinating disorders (e.g., neurotrauma-induced inflammation, vascular injury, hypoxia, autoimmune attack). Currently in preclinical evaluation for undisclosed future indications.
• Gene-Edited Neural Cell Therapies Genetically modified (gene-edited) neural cell therapy candidates being developed alongside Neurona's unmodified cell therapies for targeted delivery of therapeutic factors to the central nervous system. Engineered to integrate stably into the CNS and deliver complex payloads in a sustainable, cell-and-dose-specific manner that overcomes the payload-capacity and biodistribution limitations of conventional gene therapy vectors.

Quantifiable outcome

• 89% median reduction in disabling seizures in low-dose unilateral MTLE with MTS cohort (N=9) during 7-12-month primary efficacy endpoint
• +9 more outcomes

Named customers8 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Eight partnerships are on record, tiered flagship / core acquisition partner, legal advisor on ucb acquisition, regulatory partnership (tier 1), patient advocacy partner for trial recruitment and disease awareness, patient advocacy partner for disease awareness, scientific founding institution and patient advocacy / awareness partner.

• UCB S.A. (Brussels, Belgium)flagship / core acquisition partnerStrategic or Co-development Partner · 17 April 2026UCB (global biopharmaceutical company) entered into a definitive agreement to acquire Neurona Therapeutics for up to US$1.15 billion (US$650M upfront + up to US$500M in potential future milestone payments) to add rezanecel (NRTX-1001), a regenerative cell therapy for drug-resistant mesial temporal lobe epilepsy, to UCB's epilepsy portfolio. The deal is expected to close by end of Q2 2026, pending anti-trust clearance and customary conditions. WSGR (Wilson Sonsini Goodrich & Rosati) advised Neurona on the transaction. This represents UCB's strategic expansion into regenerative medicine, building on its 30-year focus on epilepsy (and following its $1.9B Zogenix acquisition in 2022). UCB reaffirmed its unchanged 2026 revenue guidance.
• Wilson Sonsini Goodrich & Rosati (WSGR)legal advisor on ucb acquisitionImplementation/ SI/ Consulting Partner · 17 April 2026Wilson Sonsini Goodrich & Rosati served as legal advisor to Neurona Therapeutics on its acquisition by UCB (announced April 17, 2026; up to US$1.15 billion deal). Transaction-related legal counsel.
• European Medicines Agency (EMA)regulatory partnership (tier 1)Others · 5 November 2025EMA granted Priority Medicines (PRIME) designation to Neurona's NRTX-1001 (now rezanecel) for the treatment of drug-resistant focal epilepsy in November 2025. PRIME enables early scientific advice, protocol assistance, accelerated assessment, and a single centralized MAA submission in the EU, supporting faster European development and regulatory review.
• U.S. Food and Drug Administration (FDA)regulatory partnership (tier 1)Others · 18 June 2024FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to NRTX-1001 in June 2024 for the treatment of focal epilepsy, supporting accelerated development and review. RMAT designation was a key enabler of the planned Phase 3 EPIC pivotal trial design and the company's BLA pathway.
• Epilepsy Foundationpatient advocacy partner for trial recruitment and disease awarenessGTM or Marketing PartnerDisease-awareness and clinical-trial recruitment partner; provides patient-facing resources on NTE001 trial website, information about clinical trials, and links to the Foundation's diversity initiatives. Featured as a co-promoted channel for NRTX-1001 trial recruitment.
• CURE Epilepsy (Citizens United for Research in Epilepsy)patient advocacy partner for disease awarenessGTM or Marketing PartnerDisease-awareness partner; co-produced the "Stem Cells & Epilepsy: A New Therapeutic Approach for Treating Drug-Resistant Epilepsy" webinar (January 2023) and featured Neurona's regenerative cell therapy in the CURE Epilepsy Impact Report (August 2025).
• UCSF (University of California, San Francisco) — founding institutionscientific founding institutionStrategic or Co-development PartnerNeurona was founded by leading-edge neuroscientists and stem cell pioneers at UCSF (Arturo Álvarez-Buylla, Arnold Kriegstein, John Rubenstein, Cory Nicholas), based on nearly two decades of MGE/interneuron research. UCSF remains both a founding institution and an active clinical trial site (Robert Knowlton, MD).
• Epilepsy Education Everywherepatient advocacy / awareness partnerGTM or Marketing PartnerListed as a patient/clinical-trial resource partner on the NTE001 trial website to support trial recruitment and patient education around drug-resistant epilepsy.

Scale indicators9 records

Recent moves6 records

Direct peers

• BlueRock Therapeutics: Bayer-owned cell therapy company developing iPSC-derived dopaminergic neurons (DA01) for Parkinson's disease using a similar pluripotent stem-cell-derived neural cell approach. Directly comparable platform architecture (hPSC → lineage-specified neurons) and clinical-stage CNS cell therapy positioning.
• Aspen Neuroscience: Autologous iPSC-derived dopamine neuron cell therapy for Parkinson's disease (ANPD001). Comparable pluripotent stem-cell-derived neuronal cell therapy for CNS disorders, with overlapping manufacturing complexity and clinical-stage milestones.
• Geron Corporation: Develops imetelstat (oligonucleotide) and historically advanced the first FDA IND for an embryonic stem cell-derived cellular therapeutic (oligodendrocyte progenitor cells for spinal cord injury). Highly comparable stem-cell-derived CNS cell therapy background; Catherine Priest of Neurona led Geron's preclinical cellular therapeutics group.
• Sana Biotechnology: Clinical-stage cell therapy company with programs spanning hypoimmune allogeneic cell therapies and in vivo cell engineering, including CNS-relevant applications. Comparable platform-style cell therapy developer with similar scale and clinical-stage profile.

Broad incumbents

• Vertex Pharmaceuticals (Cell Therapy Programs): Through the ViaCyte acquisition and its VX-880/VX-264 programs, Vertex is a leading commercial-stage player in stem-cell-derived cell therapies. While focused on diabetes rather than CNS, the platform (encapsulated stem-cell-derived cells) and cGMP manufacturing infrastructure are directly analogous to Neurona's MGE platform.
• uniQure: Clinical-stage gene therapy company with CNS programs (e.g., AMT-130 for Huntington's disease). Represents a competing modality for refractory CNS disorders, particularly against Neurona's gene-edited neural cell therapy pipeline, with overlapping clinical-stage milestones and regulatory pathway dynamics.
• Prevail Therapeutics (Eli Lilly): Lilly-owned gene therapy subsidiary developing AAV-based therapies for neurodegenerative diseases including Parkinson's and frontotemporal dementia. Comparable CNS-targeted clinical-stage pipeline with similar regulatory pathway considerations (RMAT/ATMP designations, cGMP AAV manufacturing).

Emerging players

• Passage Bio: Clinical-stage AAV gene therapy company targeting rare CNS disorders (GM1 gangliosidosis, Krabbe, frontotemporal dementia). Comparable clinical-stage CNS modality targeting genetically defined refractory populations, though using viral gene delivery rather than cell therapy.
• Taysha Gene Therapies: Clinical-stage CNS gene therapy company developing AAV-based therapies for rare neurological diseases including Rett syndrome and GM1 gangliosidosis. Similar clinical-stage profile and CNS focus as Neurona, representing an alternative modality for refractory neurological disorders.
• Nkarta: Clinical-stage allogeneic NK cell therapy company. Comparable allogeneic cell therapy manufacturing paradigm, cGMP scaling challenges, and clinical-stage infrastructure; Alexis van Lingen (Neurona VP of Quality) previously held the same role at Nkarta, indicating operational comparability.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/neurona-therapeutics

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Funding overview

Funding rounds13 records

Investors23 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neurona Therapeutics